
CHANGES TO THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES

The Board of Directors (the “**Board**”) of OUE Lippo Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform the shareholders that Mr. Johji Sato has resigned as an Independent and Non-Executive Director of the Company with effect from 30 October 2021 for personal reasons as disclosed in a separate announcement released to SGX-ST today and accordingly, he shall also cease as a member of the Audit and Risk Committee (“**ARC**”) of the Company with effect from that date.

Consequent to the above changes, the Board and the ARC will be reconstituted as follows with effect from 30 October 2021:

Board of Directors

Mr. Lee Yi Shyan	-	<i>Non-Independent and Non-Executive Chairman</i>
Mr Yet Kum Meng	-	<i>Chief Executive Officer and Executive Director</i>
Mr. Tadahiro Kiyosu	-	<i>Non-Independent and Non-Executive Director</i>
Mr. Roger Tan Chade Phang	-	<i>Lead Independent and Non-Executive Director</i>
Mr. Eric Sho Kian Hin	-	<i>Independent Director and Non-Executive Director</i>
Mr. Jackson Tay Eng Kiat	-	<i>Independent Director and Non-Executive Director</i>

Audit and Risk Committee

Mr. Eric Sho Kian Hin	-	<i>Chairman</i>
Mr. Roger Tan Chade Phang	-	<i>Member</i>
Mr. Jackson Tay Eng Kiat	-	<i>Member</i>

There will be no changes to the compositions of the Nominating and Remuneration Committee (“**NRC**”).

The Board would like to take this opportunity to extend its sincere appreciation to Mr. Johji Sato for his invaluable contribution to the Company and the Group. The Board, through the NRC, will continue to examine its structure, size, independence and diversity to ensure that it continues to provide the appropriate balance and mix of skills, knowledge and experience for effective decision making. The Board, if deemed necessary, following a review of its composition, will identify suitable candidate, and will make the required announcement(s) in accordance with applicable Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist (the “**Catalist Rules**”).

Further details of Mr Johji Sato’s cessation which is required to be disclosed pursuant to the Catalist Rules have been set out in a separate announcement released to SGX-ST today.

By Order of the Board
OUE Lippo Healthcare Limited

Mr Yet Kum Meng
Chief Executive Officer and Executive Director
14 October 2021

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.